PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity

Author:

Nam Hwanhee1,Lee Esder2,Yang Hichang2,Lee Kyeyoon2,Kwak Taeho2,Kim Dain2,Kim Hyemin2,Yang Mihwa2,Yang Younjoo2,Son Seungwan2,Nam Young-Hyean2,Minn Il13ORCID

Affiliation:

1. Institute for NanoBioTechnology, Johns Hopkins University , Baltimore, MD 21218, United States

2. NuriBio Co., Ltd , Anyang-si, Gyeonggi-Do, 14058, Republic of Korea

3. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions , Baltimore, MD 21287, United States

Abstract

Abstract Real-time polymerase chain reaction (real-time PCR) is a powerful tool for the precise quantification of nucleic acids in various applications. In cancer management, the monitoring of circulating tumor DNA (ctDNA) from liquid biopsies can provide valuable information for precision care, including treatment selection and monitoring, prognosis, and early detection. However, the rare and heterogeneous nature of ctDNA has made its precise detection and quantification challenging, particularly for ctDNA containing hotspot mutations. We have developed a new real-time PCR tool, PROMER technology, which enables the precise and sensitive detection of ctDNA containing cancer-driven single-point mutations. The PROMER functions as both a PRObe and priMER, providing enhanced detection specificity. We validated PROMER technology using synthetic templates with known KRAS point mutations and demonstrated its sensitivity and linearity of quantification. Using genomic DNA from human cancer cells with mutant and wild-type KRAS, we confirmed that PROMER PCR can detect mutant DNA. Furthermore, we demonstrated the ability of PROMER technology to efficiently detect mutation-carrying ctDNA from the plasma of mice with human cancers. Our results suggest that PROMER technology represents a promising new tool for the precise detection and quantification of DNA containing point mutations in the presence of a large excess of wild-type counterpart.

Funder

Nuribio Co., Ltd

Publisher

Oxford University Press (OUP)

Reference48 articles.

1. Liquid biopsy: from discovery to clinical application;Alix-Panabieres;Cancer Discov,2021

2. [Nuclear acids in human blood plasma];Mandel;C R Seances Soc Biol Fil,1948

3. Free DNA in the serum of cancer patients and the effect of therapy;Leon;Cancer Res,1977

4. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention;Lennon;Science,2020

5. Circulating tumor DNA and liquid biopsy in oncology;Cescon;Nat Cancer,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3